FDA feedback clears path for Phase 3 Fasedienol development in social anxiety disorder

Vistagen reported fiscal Q2 financial results and stated it received constructive FDA feedback to advance its Phase 3 study for fasedienol in social anxiety disorder, aiming to maintain flexibility in operations.